Bayer Aktiengesellschaft (ETR:BAYN)

Germany flag Germany · Delayed Price · Currency is EUR
21.03
+0.08 (0.36%)
Apr 17, 2025, 5:35 PM CET
-19.36%
Market Cap 20.66B
Revenue (ttm) 46.61B
Net Income (ttm) -2.55B
Shares Out 982.42M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE 4.64
Dividend 0.11 (0.52%)
Ex-Dividend Date Apr 28, 2025
Volume 2,717,670
Average Volume 4,946,285
Open 21.12
Previous Close 20.96
Day's Range 20.71 - 21.13
52-Week Range 18.38 - 31.03
Beta 1.01
RSI 45.86
Earnings Date May 13, 2025

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]

Sector Healthcare
Founded 1863
Employees 90,587
Stock Exchange Deutsche Börse Xetra
Ticker Symbol BAYN
Full Company Profile

Financial Performance

In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.

Financial Statements

News

Bayer CEO: targeting US state regulation to stem glyphosate costs

Bayer is lobbying U.S. states to adjust their regulatory framework in its battle to wind down costly litigation over its weedkiller glyphosate, the German chemicals company's CEO said in a draft speec...

1 day ago - Reuters

Bayer Unveils $44 Million Investment in Myerstown, PA Manufacturing Facility, Renewing Commitment to U.S. Innovation, Health and Community

MYERSTOWN, Pa.--(BUSINESS WIRE)--Today, Bayer proudly celebrated the grand opening of its new 70,000 square foot expansion at its Myerstown facility, following a $44 million investment in 2022. This s...

2 days ago - Business Wire

Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting.

2 days ago - Business Wire

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns

The German company cites mounting costs from lawsuits blaming Roundup for causing cancer.

4 days ago - WSJ

Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing

The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc. (...

4 days ago - Benzinga

EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Euro...

4 days ago - Wallstreet:Online

FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation

The U.S. Food And Drug Administration (FDA) granted full approval to Bayer AG’s (OTC: BAYRY) Vitrakvi (larotrectinib) for adult and pediatric patients with solid tumors that have a neurotrophic recep...

8 days ago - Benzinga

Bayer renews bid for US Supreme Court to curb glyphosate cases

Bayer said on Friday it was again petitioning the U.S. Supreme Court to sharply limit legal claims that its Roundup weedkiller causes cancer, seeking to avoid potentially billions of dollars in damage...

14 days ago - Reuters

Bayer announces filing of petition to U.S. Supreme Court for review of Durnell Roundup™ case

LEVERKUSEN, Germany--(BUSINESS WIRE)--Today Bayer – through its indirect subsidiary Monsanto – filed its petition for a writ of certiorari with the U.S. Supreme Court in the Durnell case, just three b...

14 days ago - Business Wire

Zone Agtech, Bayer and Axceta Sign Agreement to Build Innovation Consortium in AgriTech and Greenhouse Technology

L'ASSOMPTION RCM, QC , April 3, 2025 /CNW/ - Bayer's Crop Science division, Zone Agtech, and Axceta have officially signed a Memorandum of Understanding (MOU) to launch a three-party collaboration aim...

15 days ago - Benzinga

Bayer exec urges EU to avoid trade war as pharma dodges tariffs (for now)

Bayer’s head of Pharmaceuticals talks to Euractiv about US tariffs, expresses scepticism over CMA, and how the discussion on RDP should be focused on increasing it for incentivising competitiveness.

15 days ago - EURACTIV.com

Bayer eyes launch of menopause relief, heart drugs this year

Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of at least $1 billion, as it seeks to strengthen its pharmaceuticals business ...

17 days ago - Reuters

Elliott held talks with private equity as it considered new Bayer campaign

US hedge fund gauged investor interest in German conglomerate’s consumer health business

23 days ago - Financial Times

Bayer acquires rights in Puhe BioPharma cancer drug candidate

Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China's Puhe BioPharma.

23 days ago - Reuters

ACC.25: Bayer Presents New Investigational Heart Failure Data and Continued Portfolio Research in Chronic Kidney Disease in Type 2 Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American Coll...

24 days ago - Business Wire

Bayer told to pay almost $2.1bn over Roundup cancer link claim

A jury in the US state of Georgia has ordered Monsanto parent Bayer to pay nearly $2.1bn (1.94bn) in damages to a man who says the companys Roundup weed killer caused his cancer, according to attorney...

24 days ago - Independent Ireland

Monsanto parent ordered to pay $2B in Roundup lawsuit damages

The company behind Roundup weedkiller herbicide was ordered to pay more than $2 billion in a man’s cancer lawsuit. According to his attorneys, John Barnes developed non-Hodgkin’s lymphoma after using ...

25 days ago - The Hill

Bayer Stock Slumps After Firm Ordered To Pay More Than $2B in Latest Roundup Case

Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged cancer risk tied to its Roundup weed killer.

25 days ago - Investopedia

Push-pull over glyphosate in Germany

Bayer is confident it can "restore" the authorisation of the controversial weedkiller.

25 days ago - EURACTIV.com

Bayer ordered to pay €1.9 billion by US court in Roundup cancer case

Pharmaceutical company Bayer took over weed killer Roundup in its acquisition of US agrochemical company Monsanto back in 2018. However, it has since been hit with thousands of cancer-related Roundup ...

25 days ago - Euronews

Dr. Mike Graham Appointed as New Head of R&D for Bayer’s Crop Science Division

Effective April 15, 2025, he will succeed Dr. Robert Reiter who has decided to retire after 27 years with the company and 34 years in the industry Dr. Mike Graham has profound expertise in R&D and agr...

25 days ago - Financial Post

Dr. Mike Graham Appointed as New Head of R&D for Bayer's Crop Science Division

MONHEIM, Germany--(BUSINESS WIRE)--Bayer announced today that Dr. Mike Graham will become the new Head of Research & Development (R&D) for Bayer's Crop Science division and serve as member of the Lead...

25 days ago - Business Wire